Core Insights - Polyrizon Ltd. has announced new preclinical data indicating that its proprietary naloxone hydrogel demonstrates superior mucoadhesion compared to an existing intranasal naloxone spray product, which may enhance opioid overdose reversal in real-world emergencies [1][5]. Group 1: Product Performance - The study utilized an ex-vivo rabbit nasal mucosa model to compare the persistence of Polyrizon's hydrogel formulation against a commercial product, revealing that Polyrizon's hydrogel maintained significantly higher levels of a fluorescence marker, indicating stronger and more durable mucosal retention (p < 0.0001) [2]. - Polyrizon's Trap and Target ™ (T&T) hydrogel exhibited significantly higher mucoadhesion levels, suggesting prolonged contact at the nasal deposition site and potentially improved bioavailability [3]. Group 2: Importance of Mucoadhesion - Enhanced mucoadhesion is critical for intranasal drug delivery, especially for emergency treatments like opioid overdose reversal, as it supports more reliable absorption and potentially faster onset of action [4]. Group 3: Company Perspective - The CEO of Polyrizon emphasized that the results validate the potential of the T&T hydrogel platform and highlight its advantages in intranasal drug delivery, marking an important milestone in advancing the Naloxone program [5]. - The new dataset builds on previously reported stability results, reinforcing the robustness of Polyrizon's formulation under various storage conditions, which collectively supports the potential for a safer and more effective intranasal naloxone product [5]. Group 4: Company Overview - Polyrizon is a development-stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens while also enhancing drug delivery through improved bioadhesion and retention [6].